<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Timing of dornase alfa inhalation for cystic fibrosis - Dentice, R - 2021 | Cochrane Library</title> <meta content="Timing of dornase alfa inhalation for cystic fibrosis - Dentice, R - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007923.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Timing of dornase alfa inhalation for cystic fibrosis - Dentice, R - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007923.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007923.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Timing of dornase alfa inhalation for cystic fibrosis" name="citation_title"/> <meta content="Ruth Dentice" name="citation_author"/> <meta content="Royal Prince Alfred Hospital" name="citation_author_institution"/> <meta content="ruth.dentice@health.nsw.gov.au" name="citation_author_email"/> <meta content="Mark Elkins" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD007923.pub6" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/03/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007923.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007923.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007923.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Combined Modality Therapy [methods]; Cystic Fibrosis [*therapy]; Deoxyribonuclease I [*administration &amp; dosage]; Drug Administration Schedule; Forced Expiratory Volume; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins [administration &amp; dosage]; Respiratory Therapy [*methods]; Time Factors; Vital Capacity" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007923.pub6&amp;doi=10.1002/14651858.CD007923.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Qh5938oe";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007923\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007923\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","ja","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007923.pub6",title:"Timing of dornase alfa inhalation for cystic fibrosis",firstPublishedDate:"Mar 9, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007923.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007923.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007923.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007923.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007923.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007923.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007923.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007923.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007923.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007923.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1594 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007923.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#CD007923-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#CD007923-sec-0128"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#CD007923-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#CD007923-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#CD007923-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#CD007923-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#CD007923-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#CD007923-sec-0122"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/appendices#CD007923-sec-0133"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/table_n/CD007923StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/table_n/CD007923StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Timing of dornase alfa inhalation for cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/information#CD007923-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ruth Dentice</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007923.pub6/information#CD007923-cr-0005">Mark Elkins</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/information/en#CD007923-sec-0142">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 March 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007923.pub6">https://doi.org/10.1002/14651858.CD007923.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007923-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007923-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007923-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007923-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007923-abs-0008">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007923-abs-0001" lang="en"> <section id="CD007923-sec-0001"> <h3 class="title" id="CD007923-sec-0001">Background</h3> <p>Inhalation of the enzyme dornase alfa reduces sputum viscosity and improves clinical outcomes of people with cystic fibrosis. This is an update of a previously published Cochrane Review. </p> </section> <section id="CD007923-sec-0002"> <h3 class="title" id="CD007923-sec-0002">Objectives</h3> <p>To determine whether the timing of dornase alfa inhalation (in relation to airway clearance techniques or morning versus evening inhalation) has an impact on objective and subjective measures of clinical efficacy in people with cystic fibrosis. </p> </section> <section id="CD007923-sec-0003"> <h3 class="title" id="CD007923-sec-0003">Search methods</h3> <p>Relevant randomised and quasi‐randomised controlled trials were identified from the Cochrane Cystic Fibrosis Trials Register, the Physiotherapy Evidence Database (PEDro), clinical trial registries and international cystic fibrosis conference proceedings. </p> <p>Date of the most recent search: 12 October 2020.</p> </section> <section id="CD007923-sec-0004"> <h3 class="title" id="CD007923-sec-0004">Selection criteria</h3> <p>Any trial of dornase alfa in people with cystic fibrosis where timing of inhalation was the randomised element in the trial with either: inhalation before compared to after airway clearance techniques; or morning compared to evening inhalation.  </p> </section> <section id="CD007923-sec-0005"> <h3 class="title" id="CD007923-sec-0005">Data collection and analysis</h3> <p>Both authors independently selected trials, assessed risk of bias and extracted data with disagreements resolved by discussion. Relevant data were extracted and, where possible, meta‐analysed. We assessed the quality of the evidence using GRADE. </p> </section> <section id="CD007923-sec-0006"> <h3 class="title" id="CD007923-sec-0006">Main results</h3> <p>We identified 115 trial reports representing 55 trials, of which five trials (providing data on 122 participants) met our inclusion criteria. All five trials used a cross‐over design. Intervention periods ranged from two to eight weeks. Four trials (98 participants) compared dornase alfa inhalation before versus after airway clearance techniques. Inhalation after instead of before airway clearance did not significantly change forced expiratory volume at one second (very‐low quality evidence). Similarly, forced vital capacity (low‐quality evidence) and quality of life (very‐low quality evidence) were not significantly affected; forced expiratory flow at 25% was significantly worse with dornase alfa inhalation after airway clearance, mean difference ‐0.17 litres (95% confidence interval ‐0.28 to ‐0.05), based on the pooled data from two small trials in children (7 to 19 years) with well‐preserved lung function. All other secondary outcomes were statistically non‐significant. </p> <p>In one trial (25 participants), morning versus evening inhalation had no impact on lung function or symptoms (low‐quality evidence). </p> </section> <section id="CD007923-sec-0007"> <h3 class="title" id="CD007923-sec-0007">Authors' conclusions</h3> <p>The current evidence derived from a small number of participants does not indicate that inhalation of dornase alfa after airway clearance techniques is more or less effective than the traditional recommendation to inhale nebulised dornase alfa 30 minutes prior to airway clearance techniques, for most outcomes. For children with well‐preserved lung function, inhalation before airway clearance may be more beneficial for small airway function than inhalation after. However, this result relied on a measure with high variability and trials with variable follow‐up. In the absence of strong evidence to indicate that one timing regimen is better than another, the timing of dornase alfa inhalation can be largely based on pragmatic reasons or individual preference with respect to the time of airway clearance and time of day. Further research is warranted. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007923-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007923-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007923-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007923-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007923-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007923-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007923-abs-0005">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007923-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007923-abs-0010">Polski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007923-abs-0002" lang="en"> <h3>The timing of inhalation of dornase alfa in people with cystic fibrosis</h3> <p><b>Review question</b> </p> <p>To determine the effect of timing of dornase alfa inhalation on measures of effectiveness in people with cystic fibrosis (in relation to airway clearance techniques or time of day). This is an update of a previously published Cochrane Review. </p> <p><b>Background</b> </p> <p>Inhaling the enzyme dornase alfa reduces the stickiness of sputum and improves clinical outcomes in people with cystic fibrosis. It is not certain whether it is better to inhale dornase alfa before or after clearing the airways with physical techniques. It is also not clear whether it is better to inhale it in the morning or in the evening. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 12 October 2020.</p> <p><b>Study characteristics</b> </p> <p>We included five trials with a total of 122 participants. In these trials the length of treatment ranged from two to eight weeks. </p> <p><b>Key results</b> </p> <p>Four of the trials compared inhaling before to inhaling after the airways had been cleared and found no overall difference in clinical outcomes. However, in children with well‐preserved lung function, inhaling of dornase alfa before airway clearance techniques was better for small airways function. However, this did not affect quality of life or other outcomes. In the remaining trial, morning versus evening inhalation had no impact on lung function or symptoms. Therefore, for many people with cystic fibrosis, the timing of dornase alfa inhalation (before or after airway clearance or the time of day) can be based on practical reasons or individual preference. </p> <p><b>Quality of the evidence</b> </p> <p>Apart from one trial published only in abstract form, the quality of the evidence ranged from low to very low. This was due to issues relating to group allocation, blinding, incomplete reporting of outcome data and the the limited age range of participants. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007923-sec-0128" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007923-sec-0128"></div> <h3 class="title" id="CD007923-sec-0129">Implications for practice</h3> <section id="CD007923-sec-0129"> <p>For children with well preserved lung function, data derived from a small number of participants indicate that inhalation of dornase alfa before airway clearance techniques may be more beneficial for small airway function, but does not affect other outcomes. In the absence of strong evidence to indicate that one timing regimen is better than another, the timing of of dornase alfa inhalation can be largely based on pragmatic reasons or individual preference with respect to the time of airway clearance and time of day. </p> </section> <h3 class="title" id="CD007923-sec-0130">Implications for research</h3> <section id="CD007923-sec-0130"> <p>The primary outcome examined by this review (forced expiratory volume at one second (FEV<sub>1)</sub>) was not affected by the timing of dornase alfa inhalation with respect to airway clearance or time of day. For the other outcomes of this review, there were some significant findings in individual trials, but further evidence is required in well‐designed trials of longer duration. To better investigate the effect on small airway function, a more sensitive measure, such as nitrogen washout, might be used. </p> <p>This review has identified few randomised controlled trials that consider the timing of dornase alfa inhalation. Given the expense in both time and money to both patients and care providers, further research is warranted to attempt to clarify an optimal regimen for dornase alfa therapy. Interestingly, in the current trials no follow‐up information regarding what participants opted to continue when the trial finished was included, this may have provided valuable insights into subjective treatment efficacy. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007923-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007923-sec-0008"></div> <div class="table" id="CD007923-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Inhalation of dornase alfa before versus after airway clearance techniques</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>DNase inhalation before versus after ACTs for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults and children with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: DNase inhalation before ACT </p> <p><b>Comparison</b>: DNase inhalation after ACT </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Inhalation after airway clearance</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Inhalation before airway clearance</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> </p> <p>change from baseline</p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.83% (95% CI ‐2.96% to 1.31%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> <p>(4 cross‐over trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊖⊖⊖</p> <p><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive MD indicates an advantage for DNase inhalation before ACT, but difference is not statistically significant. </p> <p>FEV<sub>1</sub> (L) also showed no significant difference between groups. </p> <p>Participants received both ACTs as cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC (% predicted)</b> </p> <p>change from baseline</p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 1.06% (95% CI ‐1.29% to 3.41%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> <p>(2 cross‐over trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive MD indicates an advantage for DNase inhalation before ACT, but difference is not statistically significant. </p> <p>FVC (L) also showed no significant difference between groups.</p> <p>Participants received both ACTs as cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of QoL and symptom scores</b> </p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> <p>(4 cross‐over trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊖⊖⊖</p> <p><b>very low</b><sup>1,2,3,</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 trials reported a variety of QoL scores (CFQ and QWB) and symptom scores covering well‐being, sputum (volume, viscosity and ease of clearance), and cough (daytime and nighttime). No outcome showed a difference due to timing of DNase inhalation in relation to ACTs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEF<sub>25-75</sub> (% predicted)</b> </p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐6.71% (95% CI ‐14.66% to 1.24%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative MD indicates an advantage for DNase inhalation after ACT, but difference is not statistically significant. </p> <p>Participants received both ACTs as cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (see comment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> <p>(4 cross‐over trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊖⊖⊖</p> <p><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistical comparisons were made. Narrative reports included a single episode of haemoptysis after 2 weeks of DNase inhalation which resolved spontaneously with continued treatment. A further trial reported 34 adverse events (27 of these were for pulmonary exacerbations, 4 for musculoskeletal injuries and 3 gastrointestinal events) in 26 out of 52 participants, but we do not know which treatment group these occurred in. 2 trials monitored nighttime cough frequency but the timing of the interventions had no impact on nocturnal cough. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Relative effect and 95% CI presented is adjusted for the cross‐over design of the trials.<br/><b>ACT</b> : airway clearance technique; <b>CFQ</b> : Cystic Fibrosis Questionnaire, <b>CI</b> : confidence interval; <b>CSS</b> : cough symptom score; <b>DNase</b> : dornase alfa; <b>FEF<sub>25-75</sub> </b> : mid‐forced expiratory volume; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MD</b> : mean difference; <b>NA</b> : not applicable; <b>QoL</b> : quality of life; <b>QWB</b> : quality of well‐being scale; <b>VAS</b>: visual analogue scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded once for high risk of bias due to lack of allocation concealment.</p> <p>2. Downgraded once for high risk of bias due to lack of blinding.</p> <p>3. Downgraded once for high risk of bias due to incomplete outcome data.</p> <p>4. Downgraded once for lack of applicability as trials included only children so results are not applicable to adults. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007923-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Morning versus evening inhalation of dornase alfa</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Morning versus evening inhalation of DNase for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults and children with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: morning DNase inhalation </p> <p><b>Comparison</b>: evening DNase inhalation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Evening inhalation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morning inhalation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> </p> <p>change from baseline</p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐1.30% (95% CI ‐4.18% to 1.58%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative MD indicates an advantage for evening DNase inhalation, but difference is not statistically significant. </p> <p>FEV<sub>1</sub> (L) also showed no significant difference between groups. </p> <p>Participants received both morning and evening DNase inhalation as cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC (% predicted)</b> </p> <p>change from baseline</p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐0.10% (95% CI ‐5.98% to 5.78%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative MD indicates an advantage for evening DNase inhalation, but difference is not statistically significant </p> <p>FVC (L) also showed no significant difference between groups.</p> <p>Participants received both morning and evening DNase inhalation as cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of QoL and symptom scores</b> </p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A variety of VAS scores reported on cough (day and night), sputum (volume and viscosity), appetite and sleep quality; none of which were significantly different as a result of the time of day the DNase was inhaled. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEF<sub>25-75</sub> (% predicted)</b> </p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (see comment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistical comparisons made. Narrative reports indicated that evening DNase inhalation did not adversely impact overnight oximetry or cough per hour recordings (but between‐group comparisons were not provided for this outcome). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Relative effect and 95% CI presented is adjusted for the cross‐over design of the trials.<br/><b>ACT</b> : airway clearance technique; <b>CI</b> : confidence interval; <b>CSS</b> : cough symptom score; <b>DNase</b> : dornase alfa; <b>FEF<sub>25-75</sub> </b> : mid‐forced expiratory volume; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MD</b> : mean difference; <b>NA</b> : not applicable; <b>QoL</b> : quality of life; <b>VAS</b>: visual analogue scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded once for lack of applicability as the trial only included children so results are not applicable to adults. </p> <p>2. Downgraded once due to incomplete outcome data.</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007923-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007923-sec-0009"></div> <section id="CD007923-sec-0010"> <h3 class="title" id="CD007923-sec-0010">Description of the condition</h3> <p>Cystic fibrosis (CF) is the most common life‐limiting autosomal recessive disorder amongst Caucasians (<a href="./references#CD007923-bbs2-0057" title="CuttingGR . Cystic fibrosis. In: RimonDL , ConnorJM , PyeritzRE , KorfBR , editors(s). Principles and Practice of Medical Genetics. 4th edition. London: Harcourt, 2002:1561-606.">Cutting 2002</a>). CF‐related pulmonary disease is the major cause of morbidity and mortality (<a href="./references#CD007923-bbs2-0055" title="BuzzettiR , SalvatoreD , BaldoE , FornerisMP , LucidiV , ManunzaD , et al. An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis. Journal of Cystic Fibrosis2009;8(4):229-37.">Buzzetti 2009</a>). </p> </section> <section id="CD007923-sec-0011"> <h3 class="title" id="CD007923-sec-0011">Description of the intervention</h3> <p>The enzyme recombinant human deoxyribonuclease (dornase alfa), has been shown to reduce the viscosity of sputum taken from people with CF by digesting the deoxyribonucleic acid (DNA) released from neutrophils (<a href="./references#CD007923-bbs2-0062" title="LiebermanJ . Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA1968;205(5):312-3.">Lieberman 1968</a>). The proprietary name of dornase alfa is Pulmozyme<sup>®</sup> (produced by Genentech Inc.). Therapy with dornase alfa over a one‐, six‐ or 12‐month period is associated with an improvement in lung function in CF (<a href="./references#CD007923-bbs2-0068" title="YangC , MontgomeryM . Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews2018, Issue 9. Art. No: CD001127. [DOI: 10.1002/14651858.CD001127.pub4]">Yang 2018</a>). </p> <p>A single daily dose of 2.5 mg of dornase alfa is not less effective than higher dosing regimens (<a href="./references#CD007923-bbs2-0013" title="EisenbergJ . Clinical development of rhDNase in the United States [Developpement clinique de la rhDNase aux Etats-Unis]. Archives de Pediatrie1995;2(7):674-8. [MEDLINE: 95392717]FuchsHJ , BorowitzD , ChristiansenD , MorrisE , NashM , RamseyB , et al. Aerosolised recombinant human DNase reduces pulmonary exacerbations and improves pulmonary function in patients with cystic fibrosis. In: Proceedings of 36th Annual Conference on Chest Disease. 1993. FuchsHJ , BorowitzDS , ChristiansenDH , MorrisEM , NashML , RamseyBW , et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. New England Journal of Medicine1994;31(10):637-42. MenzinJ , OsterG , DaviesL , DrummondMF , GreinerW , LucioniC , et al. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. International Journal of Technology Assessment in Health Care1996;12(1):52-61. [MEDLINE: 97028227]OsterG , HuseDM , LacerMJ , ReganMM , FuchsHJ . Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Annals of Pharmacotherapy1995;29(5):459-64. RamseyB , For the Pulmozyme™ (rhDNase) Study Group. A summary of the results of the phase III multicenter clinical trial: Aerosol administration of recombinant human DNase reduces the risk of respiratory tract infections and improves pulmonary function in patients with cystic fibrosis. Pediatric Pulmonology1993;16(Suppl 9):152-3. von derSchulenburgJM , GreinerW , von derHardtH . Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis [Soziookonomische Evaluation des Einflusses von rhDNase auf die Kosten der Behandlung von Infektionen der Atemwege bei Patienten mit zystischer Fibrose]. Medizinische Klinik1995;90(4):220-4. ">Fuchs 1994</a>; <a href="./references#CD007923-bbs2-0033" title="RamseyBW , AstleySJ , AitkenML , BurkeW , ColinAA , DorkinHL , et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. American Review of Respiratory Disease1993;148(1):145-51. ">Ramsey 1993</a>). </p> </section> <section id="CD007923-sec-0012"> <h3 class="title" id="CD007923-sec-0012">How the intervention might work</h3> <p>Traditionally, people with CF have been advised to nebulise dornase alfa 30 minutes prior to airway clearance techniques. This recommendation is based on evidence that Pulmozyme<sup>®</sup> makes CF sputum pourable within 30 minutes (<a href="./references#CD007923-bbs2-0066" title="ShakS , CaponDJ , HellmissR , MarstersSA . Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proceedings of the National Academy of Sciences USA1990;87(23):9188-92.">Shak 1990</a>). Alternatively, it is also hypothesised that dornase alfa deposition to peripheral airways may be improved after airway clearance techniques have cleared the larger central airways. </p> <p>Theoretical arguments can also be put forward to support morning inhalation of dornase alfa. Given that spontaneous mucociliary clearance is faster during waking hours than sleep (<a href="./references#CD007923-bbs2-0054" title="BatemanJR , PaviaD , ClarkSW . The retention of lung secretions during the night in normal subjects. Clinical Science and Molecular Medicine. Supplement1978;55(6):523-7.">Bateman 1978</a>), morning inhalation of dornase alfa may capitalise on faster daytime mucociliary clearance and on the clearance effects of daytime activities such as exercise (<a href="./references#CD007923-bbs2-0067" title="WolffRK , DolovichMB , ObminskiG , NewhouseMT . Effects of exercise and eucapnic hyperventilation on bronchial clearance in man. Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology1977;43(1):46-50.">Wolff 1977</a>). Some people with CF find evening inhalation more convenient or report that it improves ease of expectoration the following morning. Since mucociliary clearance and coughing are suppressed overnight, evening inhalation of dornase alfa may increase its dwell time in the airways, possibly increasing its clinical efficacy. However, evening inhalation could theoretically induce cough and impair sleep quality. </p> </section> <section id="CD007923-sec-0013"> <h3 class="title" id="CD007923-sec-0013">Why it is important to do this review</h3> <p>CF is associated with a high treatment burden in terms of time and money for both people with the disease and for their care providers. Given the high costs specifically associated with dornase alfa therapy, efforts to optimise the timing of inhalation for optimal clinical efficacy are important. This is an update of a previously published Cochrane Review (<a href="./references#CD007923-bbs2-0069" title="DenticeR , ElkinsM . Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database of Systematic Reviews2011, Issue 5. Art. No: CD007923. [DOI: 10.1002/14651858.CD007923.pub2]">Dentice 2011</a>; <a href="./references#CD007923-bbs2-0070" title="DenticeR , ElkinsM . Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD007923. [DOI: 10.1002/14651858.CD007923.pub3]">Dentice 2013</a>; <a href="./references#CD007923-bbs2-0071" title="DenticeR , ElkinsM . Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: CD007923. [DOI: 10.1002/14651858.CD007923.pub5]">Dentice 2018</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007923-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007923-sec-0014"></div> <p>To determine whether the timing of dornase alfa inhalation (in relation to airway clearance techniques or morning versus evening inhalation) has an impact on objective and subjective measures of clinical efficacy in people with CF. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007923-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007923-sec-0015"></div> <section id="CD007923-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007923-sec-0017"> <h4 class="title">Types of studies</h4> <p>Controlled clinical trials (published and unpublished). Trials with either random allocation and quasi‐random allocation (e.g. where there is alternate allocation to groups) were included. </p> </section> <section id="CD007923-sec-0018"> <h4 class="title">Types of participants</h4> <p>People of all ages and of both sexes with CF diagnosed by genetic testing or evidence on sweat chloride or nasal potential difference, including all degrees of disease severity. </p> </section> <section id="CD007923-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Any dornase alfa trial in people with CF where timing of inhalation was the randomised element in the trial protocol: </p> <p> <ol id="CD007923-list-0001"> <li> <p>inhalation up to six hours before airway clearance techniques compared to inhalation up to six hours after airway clearance techniques; </p> </li> <li> <p>morning compared to evening inhalation with any definition provided by the author. If not defined, we accepted midnight to midday as morning and midday to midnight as evening. </p> </li> </ol> </p> <p>Dornase alfa treatment given as a minimum of a single dose of at least 2.5 mg.</p> </section> <section id="CD007923-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD007923-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD007923-list-0002"> <li> <p>Lung function (absolute change and change in per cent (%) predicted)</p> <ol id="CD007923-list-0003"> <li> <p>forced expiratory volume at one second (FEV<sub>1</sub>) </p> </li> <li> <p>forced vital capacity (FVC)</p> </li> </ol> </li> <li> <p>Measures of quality of life and symptom scores (including cough or subjective ease of clearance) </p> </li> </ol> </p> </section> <section id="CD007923-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007923-list-0004"> <li> <p>Measures of sputum clearance, including measures of mucociliary clearance and objective measures of sputum volume </p> </li> <li> <p>Measures of exercise capacity</p> </li> <li> <p>Mortality</p> </li> <li> <p>Other pulmonary parameters</p> <ol id="CD007923-list-0005"> <li> <p>forced expiratory flow between 25% and 75% of the vital capacity (FEF<sub>25-75</sub>) </p> </li> <li> <p>maximal instantaneous forced flow when 25% of the forced vital capacity remains to be exhaled (FEF<sub>25</sub>) </p> </li> <li> <p>total lung capacity (TLC)</p> </li> <li> <p>residual volume (RV)</p> </li> <li> <p>functional residual capacity (FRC)</p> </li> </ol> </li> <li> <p>Frequency of exacerbations of respiratory infection where a clear definition is described demonstrating an increase in symptoms or a decline in pulmonary function </p> <ol id="CD007923-list-0006"> <li> <p>admission rates to hospital (defined as either number of inpatient hospital admissions or days as a hospital inpatient) </p> </li> <li> <p>courses of IV antibiotics (whether received in hospital or in the home)</p> </li> <li> <p>outpatient treatments (presentations to hospital, unscheduled visits to the doctor)</p> </li> </ol> </li> <li> <p>Adherence to treatment along with other treatments while the protocol for inhalation timing is followed </p> </li> <li> <p>Adverse effects such as bronchospasm, cough and acute decline in pulmonary function</p> </li> </ol> </p> </section> </section> </section> <section id="CD007923-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We formulated a comprehensive search strategy in an attempt to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress). </p> <section id="CD007923-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Cystic Fibrosis and Genetic Disorders Group's Information Specialist conducted a systematic search of the Group's Cystic Fibrosis Trials Register for relevant trials using the following term: dornase alfa.<br/><br/>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching the abstract books of three major CF conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group's <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of last search of the Group's Cystic Fibrosis Register: 12 October 2020.</p> <p>We also searched the <a href="http://www.pedro@fhs.usyd.edu.au" target="_blank">Physiotherapy Evidence Database</a> (PEDro) for all years available (17 December 2020) (<a href="./appendices#CD007923-sec-0134">Appendix 1</a>; <a href="./appendices#CD007923-sec-0135">Appendix 2</a>; <a href="./appendices#CD007923-sec-0136">Appendix 3</a>; <a href="./appendices#CD007923-sec-0137">Appendix 4</a>). </p> <p>In addition to the above, we carried out further searches of the following clinical trial registers (17 December 2020): </p> <p> <ul id="CD007923-list-0007"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.ClinicalTrials.gov</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (<a href="./appendices#CD007923-sec-0138">Appendix 5</a>). </p> </li> </ul> </p> </section> <section id="CD007923-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We hand‐searched the Australia and New Zealand CF Conference Proceedings (1999 to 2019). </p> <p>We also contacted Roche in an attempt to identify further relevant trials. Experts in the use of dornase alfa inhalation were also contacted. </p> </section> </section> <section id="CD007923-sec-0026"> <h3 class="title" id="CD007923-sec-0026">Data collection and analysis</h3> <section id="CD007923-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Both authors independently selected the trials to be included in the review, with disagreements resolved by discussion. </p> </section> <section id="CD007923-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Each author independently extracted data from included trials using a standardised data extraction form. We resolved any disagreements by discussion. Where data were absent or difficult to interpret in the presented form the authors contacted the trial author in an attempt to gain the information required to evaluate trial quality or facilitate data analysis, or both. </p> <section id="CD007923-sec-0029"> <h5 class="title">For change‐from‐baseline data:</h5> <p>Where the mean difference (MD) and standard error (SE) of the MD were available, we entered these directly into the meta‐analysis. If only group means and standard deviations (SD) were available, we planned the following analysis. We planned to calculate the MD by subtraction of one group mean from the other. We planned to impute the SD of the differences from that obtained from raw data in another included trial that used the same measurement scale, and was most similar in terms of the degree of measurement error and the time period between baseline and final value measurement. We then planned to calculate the SEs using the formula: imputed SD / √n. However, we obtained MD and SE of the MD for all included trials in the current review. </p> </section> <section id="CD007923-sec-0030"> <h5 class="title">For final‐value data:</h5> <p>Where the between‐group MD and SE of the MD were available, we entered these directly into the meta‐analysis. Where these were not available, we used the MD and the P value from the paired t‐test to calculate the SE around the MD. </p> <p>We planned to report outcomes at up to one week, between one week and two months, and more than two months. However, the included trials all had intervention arms of two to eight weeks and thus outcomes were reported within a single subdivision. We plan to use the other subdivisions if trials of shorter or longer duration are included in future updates of this review. </p> </section> </section> <section id="CD007923-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Each author independently determined the risk of bias for each trial following the domain‐based evaluation as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007923-bbs2-0061" title="HigginsJP ,   SavovićJ , PageMJ , ElbersRG ,   SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020</a>). We assessed the following domains as having either a low risk, unclear risk or high risk of bias: </p> <p> <ol id="CD007923-list-0008"> <li> <p>randomisation;</p> </li> <li> <p>concealment of allocation;</p> </li> <li> <p>blinding (of participants, personnel and outcome assessors);</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other sources of bias.</p> </li> </ol> </p> <p>We resolved any disagreements by discussion. In addition, each author independently rated each trial on the PEDro Scale (<a href="./references#CD007923-bbs2-0063" title="MaherCG , SherringtonC , HerbertRD , Moseley AM and ElkinsM . Reliability of the PEDro Scale for Rating Quality of Randomized Controlled Trials. Physical Therapy2003;83(8):713-21.">Maher 2003</a>), using published and unpublished data from the trial authors. Note that these scores may differ slightly from those on the <a href="http://www.pedro.org.au" target="_blank">PEDro database</a> as those are based on the published versions only. </p> </section> <section id="CD007923-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data we used the risk ratio (RR) with 95% confidence intervals (95% CIs) as a measure of treatment effect with an intention‐to‐treat analysis. For continuous data we recorded the difference in mean change from baseline and SD (or SEs) for each group, or the final group means and SDs if change data were unavailable. We calculated a pooled estimate of treatment effect using the MD with 95% CIs. </p> </section> <section id="CD007923-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>We incorporated data from cross‐over trials into the meta‐analyses using the generic inverse variance method, involving expression of data in terms of the paired MDs between treatments and their SE. We calculated these values either from paired individual patient data provided by authors, or by calculation of MDs between interventions and their SE from means, SDs and P values reported in the manuscript (<a href="./references#CD007923-bbs2-0059" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). If parallel trials are included in future versions of this review, we intend to combine data from parallel‐designed trials with those from cross‐over trials in the meta‐analyses where appropriate. Otherwise we will consider parallel‐designed and cross‐over trials separately. If necessary, we will calculate the SEs in parallel‐designed trials from the MDs between treatments and their CIs. </p> </section> <section id="CD007923-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>Where data were absent or difficult to interpret in the presented form, the authors contacted the trial authors in an attempt to obtain the data in a form that would facilitate data analysis. </p> </section> <section id="CD007923-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We estimated the statistical heterogeneity using the I² value (<a href="./references#CD007923-bbs2-0060" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). We considered heterogeneity of 0% to 40% as low, 30% to 60% as moderate, 50% to 90% as substantial and 75% to 100% as considerable. </p> </section> <section id="CD007923-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias using a funnel plot had we been able to identify 10 trials, bearing in mind that there are other reasons for funnel plot asymmetry, so this should be interpreted with caution. Due to insufficient data we are currently unable to do this, but plan to undertake this analysis if we include sufficient trials in future updates of this review. If we suspected outcome reporting bias, we contacted the trial authors to find out if they measured and analysed an outcome and obtained the data. We contacted experts in the field to ensure unpublished trials were located. </p> </section> <section id="CD007923-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We performed meta‐analyses using a fixed‐effect model. In future versions of the review, if we observe substantial heterogeneity, as defined above, we will use a random‐effects model. </p> </section> <section id="CD007923-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned a subgroup analysis excluding trials delivering dornase alfa more than 30 minutes either side of physiotherapy in a subgroup analysis, but no eligible trial warranted this action. </p> </section> <section id="CD007923-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses by excluding trials of low quality (less than 5/10 on the PEDro Scale (<a href="./references#CD007923-bbs2-0058" title="deMortonNA . The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. Australian Journal of Physiotherapy2009;55(2):129-33.">de Morton 2009</a>; <a href="./references#CD007923-bbs2-0063" title="MaherCG , SherringtonC , HerbertRD , Moseley AM and ElkinsM . Reliability of the PEDro Scale for Rating Quality of Randomized Controlled Trials. Physical Therapy2003;83(8):713-21.">Maher 2003</a>)). We planned sensitivity analysis by excluding cross‐over trials, however, our current search did not identify any eligible parallel trials. </p> </section> <section id="CD007923-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>In a post hoc change, we have presented two summary of findings tables, one for each comparison (<a href="./full#CD007923-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD007923-tbl-0002">summary of findings Table 2</a>). We have included the following outcomes: FEV<sub>1</sub>, FVC, measures of quality of life and symptoms scores, FEF<sub>25-75</sub>, and adverse events. </p> <p>We determined the quality of the evidence using the GRADE approach; and downgraded evidence in the presence of a high risk of bias in at least one trial, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results, high probability of publication bias. We downgraded evidence by one level if we considered the limitation to be serious and by two levels if very serious. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007923-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007923-sec-0041"></div> <section id="CD007923-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD007923-sec-0043"> <h4 class="title">Results of the search</h4> <p>The electronic searches identified 125 trial reports which represented 58 trials. Of these, four trials met our inclusion criteria (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>; <a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). A further trial was identified in international CF conference proceedings in poster format (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>). The five included trials provided data for 122 participants. Eighteen reports (representing nine trials) were disregarded on title alone and we excluded 48 trials, predominantly because they did not address the timing issue of dornase alfa inhalation (<a href="#CD007923-sec-0055">Excluded studies</a>). One of these trials did not precisely match either of the two comparisons specified for this review, i.e. before versus after airway clearance techniques and morning versus evening inhalation (<a href="./references#CD007923-bbs2-0053" title="WilsonCJ , RobbinsLJ , MurphyJM , ChangAB . Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial. Pediatric Pulmonology2007;42(12):1110-6. [MEDLINE: 96279782]">Wilson 2007</a>). However, the comparison it examined (short versus long dwell time) is relevant to the broad topic of this review. Therefore, we intend to add an additional comparison to the next version of this review to allow inclusion of trials comparing long versus short dwell time. This is discussed further in the <a href="#CD007923-sec-0122">Discussion</a> section of this review. </p> </section> <section id="CD007923-sec-0044"> <h4 class="title">Included studies</h4> <p>We included five trials, which provided data for 122 participants; one trial has not yet been published in full but has been presented as a poster at a conference (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>). Four trials investigated the impact of timing in relation to airway clearance physiotherapy (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). One trial investigated the issue of morning versus evening inhalation (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). </p> <section id="CD007923-sec-0045"> <h5 class="title">Inhalation before versus after airway clearance techniques</h5> <section id="CD007923-sec-0046"> <h6 class="title">Trial characteristics</h6> <p>Four cross‐over trials (98 participants) investigated the impact of timing in relation to airway clearance techniques. The duration of intervention blocks were two weeks (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>), three weeks (<a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>) and eight weeks (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>). One trial had a two‐week washout between intervention arms (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). The longest trial (four months duration with two eight‐week intervention arms) was small in sample size and experienced significant dropouts (three out of eight participants); limited data were provided in conference poster proceedings and additional information was provided by the author (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>). </p> </section> <section id="CD007923-sec-0047"> <h6 class="title">Participants</h6> <p>Clarification of participant data was requested from the authors of the four trials.</p> <p>Three trials included children (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). The participants had mean ages of 10.7 years (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>), 11 years (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>), and 12 years (<a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). In these participants, FEV<sub>1</sub> was well preserved at 83%, 81% and 88% predicted respectively. The children had a clinically stable baseline for two to four weeks leading into two trials (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>) and at time of entry in one trial (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>). </p> <p>One trial included adults only; mean age 27 years, but with a broad age range (19 to 67 years) (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>). The adult trial included participants with a broad range of lung function (FEV<sub>1</sub> 20% to 97% predicted), who were clinically stable for the two weeks leading into the trial. </p> <p>Participants were on maintenance dornase alfa in two trials (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). In the remaining two trials the participants were dornase alfa naive (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). </p> </section> <section id="CD007923-sec-0048"> <h6 class="title">Interventions</h6> <p>The duration of each timing intervention ranged from two to eight weeks; two trials had an intervention block of two weeks, one of three weeks and one of eight weeks. </p> <p>One trial provided limited information other than the description "delivery before airway clearance techniques compared to delivery after airway clearance" (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>). </p> <p>In the three remaining trials, when dornase alfa was delivered first, it was inhaled 30 minutes before airway clearance techniques (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). Inhalation after airway clearance was immediate in two trials (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>) and 30 minutes after in one trial (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). All three included a placebo, thus two inhalations were performed for a single session of airway clearance techniques. The clearance technique was stated as positive expiratory pressure (PEP) in the majority, but some also noted active cycle of breathing techniques, Flutter, autogenic drainage, or postural drainage and percussion. </p> </section> <section id="CD007923-sec-0049"> <h6 class="title">Outcomes measured</h6> <p>All four trials looked at improvements in lung function (FEV<sub>1</sub>) at the conclusion of the intervention arm. Some reported data for FVC, FEF<sub>25-75</sub> and FEF<sub>25</sub>. A variety of quality of life and symptom scores were reported. All trials reported the incidence of any adverse events. All trials except one reported adherence (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>). Data were supplied by the investigators of all trials to supplement the information that was available in their abstract and poster (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). </p> </section> </section> <section id="CD007923-sec-0050"> <h5 class="title">Morning versus evening inhalation</h5> <section id="CD007923-sec-0051"> <h6 class="title">Trial characteristics</h6> <p>One randomised, blinded, cross‐over, placebo‐controlled trial (providing data for 24 participants) investigated the issue of morning (on waking) versus evening (pre‐bedtime) inhalation (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). </p> </section> <section id="CD007923-sec-0052"> <h6 class="title">Participants</h6> <p>We requested clarification of participant data from the authors of this trial. It was a trial of children whose mean age was 13 years old (range 6 years to 19 years). Their mean FEV<sub>1</sub> was 75% predicted and they were described as clinically stable in the month prior to the trial. Participants were on maintenance dornase alfa. </p> </section> <section id="CD007923-sec-0053"> <h6 class="title">Interventions</h6> <p>Each intervention block in this trial lasted for two weeks; there was no washout period reported. </p> <p>The clearance technique used in this trial was predominantly PEP mask (62%), with autogenic drainage (17%), Flutter (13%) or a combination in smaller numbers. The clearance technique was performed for 30 minutes post morning inhalation, with a placebo being used so that inhalations were performed twice daily. </p> </section> <section id="CD007923-sec-0054"> <h6 class="title">Outcomes measured</h6> <p>This trial reported on lung function (FEV<sub>1</sub>, FVC, FEF<sub>25</sub>), symptom scores (VAS for cough and cough symptom scoring (CSS) day and night, sleep quality, sputum viscosity and amount), adherence and adverse events. </p> </section> </section> </section> <section id="CD007923-sec-0055"> <h4 class="title">Excluded studies</h4> <p>A total of 93 papers representing 48 trials were added to the <a href="#CD007923-sec-0055">Excluded studies</a> section, predominantly because they did not address timing of dornase alfa inhalation. Furthermore, nine were not RCTs, two did not study people with CF, and three did not involve dornase alfa. A further trial considered the impact of dornase alfa dwell time in the lung before airway clearance techniques. It compared a short dwell (median of 0.25 hours) to a long dwell (median of 11.1 hours) (<a href="./references#CD007923-bbs2-0053" title="WilsonCJ , RobbinsLJ , MurphyJM , ChangAB . Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial. Pediatric Pulmonology2007;42(12):1110-6. [MEDLINE: 96279782]">Wilson 2007</a>). While participants were randomised to morning or evening inhalation of dornase alfa, the data were not analysed in relation to this. We considered that long or short dwell time is a separate issue. This is discussed further in the <a href="#CD007923-sec-0122">Discussion</a> section. </p> </section> </section> <section id="CD007923-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias of each trial using criteria as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007923-bbs2-0061" title="HigginsJP ,   SavovićJ , PageMJ , ElbersRG ,   SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020</a>). For each trial we assessed the following: randomisation; concealment of allocation; blinding (of participants, personnel and outcome assessors); outcome data reporting (incomplete or selective). We also completed the PEDro Scale for the included trials (<a href="./references#CD007923-bbs2-0058" title="deMortonNA . The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. Australian Journal of Physiotherapy2009;55(2):129-33.">de Morton 2009</a>; <a href="./references#CD007923-bbs2-0063" title="MaherCG , SherringtonC , HerbertRD , Moseley AM and ElkinsM . Reliability of the PEDro Scale for Rating Quality of Randomized Controlled Trials. Physical Therapy2003;83(8):713-21.">Maher 2003</a>). The PEDro Scale assesses whether allocation was truly random, whether allocation was concealed, whether the groups were comparable at baseline, whether participants, therapists and assessors were blinded, whether follow‐up exceeded 85% for any outcome, whether analysis was by intention‐to‐treat and whether between group comparisons were made and reported with point estimates and measures of variability (for more detail, <i>see</i><a href="http://www.pedro.org.au/english/downloads/pedro-scale/" target="_blank">PEDro Scale</a>). </p> <p>Among the trials of dornase alfa inhalation before versus after airway clearance, PEDro scores ranged from three (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>) to nine (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). The single trial of dornase alfa inhalation in the morning versus the evening also scored nine (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). All these scores are included in the table <a href="./references#CD007923-sec-0148" title="">Characteristics of included studies</a>. </p> <section id="CD007923-sec-0057"> <h4 class="title">Allocation</h4> <section id="CD007923-sec-0058"> <h5 class="title">Inhalation before versus after airway clearance techniques</h5> <section id="CD007923-sec-0059"> <h6 class="title">Generation of sequence</h6> <p>No trials reported the method of generation of the random sequence. Two trials reported using block randomisation (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>) and thus have a low risk of bias. However, two trials stated that they were randomised but did not provide methodology (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). Thus the overall risk of bias due to the method of generation of the random sequence is unclear. </p> </section> <section id="CD007923-sec-0060"> <h6 class="title">Concealment of allocation</h6> <p>Among the trials of dornase alfa inhalation before versus after airway clearance techniques, allocation was concealed in two trials which both used independent distant pharmacies and which we judged to have a low risk of bias (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). Allocation concealment was unclear in one trial which we judged to have an unclear risk of bias (<a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>), and was unconcealed in the final trial which we judged to have a high risk of bias (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>). We judged the risk of bias due to unconcealed allocation across all trials to be moderate.<br/>  </p> </section> </section> <section id="CD007923-sec-0061"> <h5 class="title">Morning versus evening inhalation</h5> <section id="CD007923-sec-0062"> <h6 class="title">Generation of sequence</h6> <p>The included trial did not report the method of sequence generation (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). Thus the risk of bias due to this is unclear. </p> </section> <section id="CD007923-sec-0063"> <h6 class="title">Allocation concealment</h6> <p>The method for concealing allocation and hence risk of bias is unclear (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). </p> </section> </section> </section> <section id="CD007923-sec-0064"> <h4 class="title">Blinding</h4> <section id="CD007923-sec-0065"> <h5 class="title">Inhalation before versus after airway clearance techniques</h5> <p>Among the trials of dornase alfa inhalation before versus after airway clearance techniques, blinding was adequate in three trials that used a double‐dummy placebo (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). Thus, the risk of bias due to lack of blinding was low in these trials. Blinding was not used in one trial, giving a high risk of bias (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>), but the proportion of data contributed by this trial was very small due to its small sample size. The overall risk of bias due to lack of blinding was therefore low. </p> </section> <section id="CD007923-sec-0066"> <h5 class="title">Morning versus evening inhalation</h5> <p>The single trial of dornase alfa inhalation in the morning versus the evening blinded participants, therapists and assessors (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). Therefore, the risk of bias was low. </p> </section> </section> <section id="CD007923-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <section id="CD007923-sec-0068"> <h5 class="title">Inhalation before versus after airway clearance techniques</h5> <p>Among the trials of dornase alfa inhalation before versus after airway clearance techniques, the number (%) of dropouts was low in three trials: 2 (4%) (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>); 0 (0%) (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>); 1 (4%) (<a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>), giving a low risk of bias. The number (%) of dropouts was high in one trial: 3 (37%) (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>), giving a high risk of bias. An intention‐to‐treat analysis was performed in two trials, giving a low risk of bias (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>). Intention‐to‐treat analysis was not performed in two trials due to dropouts as a consequence of pulmonary exacerbations, giving a high risk of bias (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). The overall risk of bias was moderate. </p> </section> <section id="CD007923-sec-0069"> <h5 class="title">Morning versus evening inhalation</h5> <p>There was one (4%) dropout in this trial and intention‐to‐treat analysis was used (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). Therefore, the risk of bias was low. </p> </section> </section> <section id="CD007923-sec-0070"> <h4 class="title">Selective reporting</h4> <section id="CD007923-sec-0071"> <h5 class="title">Inhalation before versus after airway clearance techniques</h5> <p>Although we did not review the trial protocols, we contacted the trial authors of the included trials requesting confirmation that the data they provided includes all outcomes measured in the trials. The authors have confirmed this for all trials, therefore giving no risk of bias due to outcome measures being omitted completely (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). However, a small number of outcomes in each trial that did not significantly differ between groups were only reported as "non‐significant" and further data could not be obtained. Therefore, overall the risk of bias due to selective reporting is low. </p> </section> <section id="CD007923-sec-0072"> <h5 class="title">Morning versus evening inhalation</h5> <p>We have contacted trial authors of the included trial requesting confirmation that the data provided includes all outcome measured in the trial (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). The trial authors confirmed that all of the outcomes measured were reported, therefore, there was no risk of bias due to outcome measures being omitted completely. However, some outcomes were only described as non‐significant without provision of data. Therefore, the overall risk of bias due to selective reporting is low. </p> </section> </section> <section id="CD007923-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <section id="CD007923-sec-0074"> <h5 class="title">Inhalation before versus after airway clearance techniques</h5> <p>No other potential sources of bias were identified for any of the trials, suggesting a low risk of bias across trials (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). </p> </section> <section id="CD007923-sec-0075"> <h5 class="title">Morning versus evening inhalation</h5> <p>No other potential sources were identified, suggesting a low risk of bias (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). </p> </section> </section> </section> <section id="CD007923-sec-0076"> <h3 class="title" id="CD007923-sec-0076">Effects of interventions</h3> <p>See: <a href="./full#CD007923-tbl-0001"><b>Summary of findings 1</b> Inhalation of dornase alfa before versus after airway clearance techniques</a>; <a href="./full#CD007923-tbl-0002"><b>Summary of findings 2</b> Morning versus evening inhalation of dornase alfa</a> </p> <p>The quality of the evidence has been graded for those outcomes included in the summary of findings tables. For the definitions of these gradings, please refer to the summary of findings tables (<a href="./full#CD007923-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD007923-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD007923-sec-0077"> <h4 class="title">Inhalation before versus after airway clearance techniques</h4> <p>There are four trials included for this comparison with a total of 102 participants (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). </p> <section id="CD007923-sec-0078"> <h5 class="title">Primary outcomes</h5> <section id="CD007923-sec-0079"> <h6 class="title">1. Lung function (absolute change and change in % predicted)</h6> <section id="CD007923-sec-0080"> <p><b>a. FEV<sub>1</sub> </b></p> <p>Four trials provided data that could be included in the meta‐analysis regarding the change in FEV<sub>1</sub> in litres (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). There was no significant between‐group difference overall, MD ‐0.03 litres (95% CI ‐0.08 to 0.03) with the trend favouring inhalation before airway clearance (<a href="./references#CD007923-fig-0001" title="">Analysis 1.1</a>). In % predicted, this between‐group difference equated to MD ‐ 0.83% predicted (95% CI ‐2.96 to 1.31) (<a href="./references#CD007923-fig-0002" title="">Analysis 1.2</a>) (very low‐quality evidence). </p> <p>Fitzgerald performed a post‐hoc subgroup analysis of the 17 participants who were colonised with <i>Pseudomonas aeruginosa</i> persistently for the two years preceding the trial (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). In this subgroup, FEV<sub>1</sub> improved significantly more when dornase alfa was inhaled after airway clearance techniques (P = 0.034). </p> </section> <section id="CD007923-sec-0081"> <p><b>b. FVC</b></p> <p>Two trials provided data regarding the change in FVC in litres (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). There was no significant between‐group difference overall, MD 0.01 litres (95% CI ‐0.05 to 0.08) with the trend favouring inhalation after airway clearance (<a href="./references#CD007923-fig-0003" title="">Analysis 1.3</a>). In % predicted, this between‐group difference equated to MD 1.06% predicted (95% CI ‐1.29 to 3.41) (<a href="./references#CD007923-fig-0004" title="">Analysis 1.4</a>) (low‐quality evidence). </p> <p>One further trial reported a non‐significant change in FVC; however, data were not provided (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>). </p> </section> </section> <section id="CD007923-sec-0082"> <h6 class="title">2. Measures of quality of life and symptom scores</h6> <p>The four trials reported a variety of quality of life and symptom scores. None changed significantly as a result of timing in relation to airway clearance techniques (very low‐quality evidence). The quality of life questionnaires included the Cystic Fibrosis Questionnaire (CFQ) (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>), the Quality of Wellbeing ("a composite of mobility scale, physical and social activity scales") (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>) and a bespoke subjective questionnaire (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>). A visual analogue scale (VAS) was frequently used to report symptom scores including: well being (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>); cough (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>); sputum volume (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>); sputum viscosity (<a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>); and ease of clearance (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>). The paper by van der Giessen also reported a cough VAS and cough symptom score for day and night (<a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). Most trials reported only that the between‐group comparison was non‐significant. However, the symptom data from one trial are presented in <a href="#CD007923-tbl-0003">Table 1</a> (<a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). </p> <div class="table" id="CD007923-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Symptom Scores from van der Giessen 2007a</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>DNase before ACT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>DNase after ACT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value (paired t‐test)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS viscosity*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0.2 to 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0.2 to 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS sputum amount*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7 (0 to 5.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1 (0.1 to 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS daytime cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7 (0 to 5.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9 (1 to 7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS nightime cough*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1 (0 to 3.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2 (0 to 5.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSS daytime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 (0 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6 (0 to 3.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSS nighttime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4 (0 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7 (0 to 2.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Data are mean (or median if asterisked) and range<br/>ACT: airway clearance technique<br/>CSS: cough symptom score<br/>VAS: visual analogue scale </p> </div> </div> </section> </section> <section id="CD007923-sec-0083"> <h5 class="title">Secondary outcomes</h5> <section id="CD007923-sec-0084"> <h6 class="title">1. Measures of sputum clearance, including measures of mucociliary clearance and objective measures of sputum volume </h6> <p>The Middleton trial reported that 24‐hour wet sputum weight and the percentage cleared during physiotherapy did not change in response to timing in relation to airway clearance techniques (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>). No other trials reported on this outcome. </p> </section> <section id="CD007923-sec-0085"> <h6 class="title">2. Measures of exercise capacity</h6> <p>Two trials reported non‐significant changes in VO<sub>2</sub> max measured by 20 or 10 metre shuttle tests (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). </p> </section> <section id="CD007923-sec-0086"> <h6 class="title">3. Mortality</h6> <p>No trial reported this outcome.</p> </section> <section id="CD007923-sec-0087"> <h6 class="title">4. Other pulmonary parameters</h6> <section id="CD007923-sec-0088"> <p><b>a. FEF<sub>25-75</sub> </b></p> <p>The impact of timing with airway clearance techniques on FEF<sub>25-75</sub> in % predicted was reported to be non‐significant (P = 0.07) in one trial (<a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>) (low‐quality evidence). </p> </section> <section id="CD007923-sec-0089"> <p><b>b. FEF<sub>25</sub> </b></p> <p>Two trials provided data that could be included in the meta‐analysis regarding the change in FEF<sub>25</sub> in litres per second (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>), with a significant between‐group difference overall, MD ‐0.17 litres per second (95% CI ‐0.28 to ‐0.05) (<a href="./references#CD007923-fig-0006" title="">Analysis 1.6</a>). In % predicted, this between‐group difference equated to MD ‐5.44 % predicted (95% CI ‐9.23 to ‐1.66) (<a href="./references#CD007923-fig-0007" title="">Analysis 1.7</a>). The participants in these trials were children aged 7 years to 19 years. </p> </section> <section id="CD007923-sec-0090"> <p><b>c. TLC</b></p> <p>No trial reported this outcome.</p> </section> <section id="CD007923-sec-0091"> <p><b>d. RV</b></p> <p>No trial reported this outcome.</p> </section> <section id="CD007923-sec-0092"> <p><b>e. FRC</b></p> <p>No trial reported this outcome.</p> </section> </section> <section id="CD007923-sec-0093"> <h6 class="title">5. Frequency of exacerbations of respiratory infection</h6> <p>An exacerbation of respiratory symptoms was reported by some authors as a cause of trial withdrawal. In the trial by van der Giessen, one out of 25 developed a pulmonary exacerbation in the first arm of the trial, during which they inhaled dornase alfa before performing airway clearance techniques. The participant was withdrawn and did not provide data for the second half of the trial (<a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). Two of three dropouts in the Anderson trial were due to exacerbations (one from each group at the end of the first intervention) (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>). </p> <section id="CD007923-sec-0094"> <p><b>a. admission rates to hospital</b></p> <p>We defined this as either number of inpatient hospital admissions or days as a hospital inpatient. The Fitzgerald paper reported this data as an adverse event (see below), but the intervention arm at the time of the event was not stated (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). </p> </section> <section id="CD007923-sec-0095"> <p><b>b. courses of IV antibiotics (whether received in hospital or in the home)</b></p> <p>Fitzgerald reported three of 52 participants required hospitalisation for intravenous antibiotics; two for exacerbations of suppurative lung disease and one with streptococcal septicaemia. The intervention group at the time of the event was not stated (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). </p> </section> <section id="CD007923-sec-0096"> <p><b>c. outpatient treatments (presentations to hospital, unscheduled visits to the doctor)</b></p> <p>No trial reported this outcome.</p> </section> </section> <section id="CD007923-sec-0097"> <h6 class="title">6. Adherence to treatment along with other treatments while the protocol for inhalation timing is followed </h6> <p>The number of returned vials was reported in two trials (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). Fitzgerald had two out of 52 withdraw as a result of protocol violations (for failing to take both inhalations) but continued analysis as intention‐to‐treat (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). The second trial reported a 98% adherence rate (range 83% to 100%) (<a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). A further trial recorded adherence for airway clearance techniques and inhalation with a daily diary but the adherence rate was not reported (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>). </p> </section> <section id="CD007923-sec-0098"> <h6 class="title">7. Adverse effects such as bronchospasm, cough and acute decline in pulmonary function</h6> <p>Four trials reported on adverse events, but we were not able to meta‐analyse the results (very low‐quality evidence). The Middleton trial reported one single episode of haemoptysis after two weeks of dornase alfa inhalation that resolved spontaneously despite continued dornase alfa treatment (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>). Fitzgerald reported 34 adverse events that occurred among 26 participants (27 were due to exacerbations with previously isolated sputum pathogens, three required hospitalisation for intravenous antibiotics, four were due to musculoskeletal injuries during usual sporting activities and three were gastrointestinal in nature); the intervention group at the time of the event was not stated (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). Cough frequency during the night was monitored by two authors as a potential adverse event without a significant impact of the intervention (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). </p> </section> </section> </section> <section id="CD007923-sec-0099"> <h4 class="title">Morning versus evening inhalation</h4> <p>One cross‐over trial investigated the issue of morning (on waking) versus evening (before bedtime) inhalation with two‐week intervention periods (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). </p> <section id="CD007923-sec-0100"> <h5 class="title">Primary outcomes</h5> <section id="CD007923-sec-0101"> <h6 class="title">1. Lung function (absolute change and change in % predicted)</h6> <section id="CD007923-sec-0102"> <p><b>a. FEV<sub>1</sub> </b></p> <p>The change in FEV<sub>1</sub> in litres was reported in one trial to be non‐significant (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>), MD 0.04 (95% CI ‐0.04 to 0.12) (<a href="./references#CD007923-fig-0008" title="">Analysis 2.1</a>). In % predicted, this between‐group difference equated to MD ‐1.30 (95% CI ‐4.18 to 1.58) (<a href="./references#CD007923-fig-0009" title="">Analysis 2.2</a>) (low‐quality evidence). </p> </section> <section id="CD007923-sec-0103"> <p><b>b. FVC</b></p> <p>The change in FVC in litres was reported in one trial to be non‐significant (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>), MD 0.07 (95% CI ‐0.02 to 0.15) (<a href="./references#CD007923-fig-0010" title="">Analysis 2.3</a>). In % predicted, this between‐group difference equated to MD ‐0.10 (95% CI ‐5.98 to 5.78) (<a href="./references#CD007923-fig-0011" title="">Analysis 2.4</a>) (low‐quality evidence). </p> </section> </section> <section id="CD007923-sec-0104"> <h6 class="title">2. Measures of quality of life and symptom scores</h6> <p>A variety of VAS scores were also reported in the van der Giessen paper: cough and CSS day and night; sputum viscosity and amount; none of which were significantly different as a result of the time of day the inhalation was performed (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>) (low‐quality evidence). The symptom data are presented in <a href="#CD007923-tbl-0004">Table 2</a>. </p> <div class="table" id="CD007923-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Symptom scores from van der Giessen 2007b</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Evening</b> </p> <p><b>Mean (SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morning</b> </p> <p><b>Mean (SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS viscosity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS sputum amount</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9 (1.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS daytime coughing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 (1.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS nighttime coughing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (2.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3 (2.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS sleep quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSS daytime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6 (0.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSS nighttime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 (0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CSS: cough symptom score<br/>SD: standard deviation<br/>VAS: visual analogue scale </p> </div> </div> </section> </section> <section id="CD007923-sec-0105"> <h5 class="title">Secondary outcomes</h5> <section id="CD007923-sec-0106"> <h6 class="title">1. Measures of sputum clearance, including measures of mucociliary clearance and objective measures of sputum volume </h6> <p>The included trial did not report this outcome.</p> </section> <section id="CD007923-sec-0107"> <h6 class="title">2. Measures of exercise capacity</h6> <p>The included trial did not report this outcome.</p> </section> <section id="CD007923-sec-0108"> <h6 class="title">3. Mortality</h6> <p>The included trial did not report this outcome.</p> </section> <section id="CD007923-sec-0109"> <h6 class="title">4. Other pulmonary parameters</h6> <section id="CD007923-sec-0110"> <p><b>a. FEF<sub>25-75</sub> </b></p> <p>The included trial did not report this outcome.</p> </section> <section id="CD007923-sec-0111"> <p><b>b. FEF<sub>25</sub> </b></p> <p>The change in FEF<sub>25</sub> in % predicted was reported to be non‐significant (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>), MD ‐3.40 (95% CI ‐9.18 to 2.38) (<a href="./references#CD007923-fig-0012" title="">Analysis 2.5</a>). </p> </section> <section id="CD007923-sec-0112"> <p><b>c. TLC</b></p> <p>The included trial did not report this outcome.</p> </section> <section id="CD007923-sec-0113"> <p><b>d. RV</b></p> <p>The included trial did not report this outcome.</p> </section> <section id="CD007923-sec-0114"> <p><b>e. FRC</b></p> <p>The included trial did not report this outcome.</p> </section> </section> <section id="CD007923-sec-0115"> <h6 class="title">5. Frequency of exacerbations of respiratory infection</h6> <p>The included trial had one withdrawal out of 25 as a result of a respiratory exacerbation, but did apply an intention‐to‐treat analysis (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). </p> <section id="CD007923-sec-0116"> <p><b>a. admission rates to hospital</b></p> <p>The included trial did not report this outcome.</p> </section> <section id="CD007923-sec-0117"> <p><b>b. courses of IV antibiotics (whether received in hospital or in the home)</b></p> <p>The included trial did not report this outcome.</p> </section> <section id="CD007923-sec-0118"> <p><b>c. outpatient treatments (presentations to hospital, unscheduled visits to the doctor)</b></p> <p>The included trial did not report this outcome.</p> </section> </section> <section id="CD007923-sec-0119"> <h6 class="title">6. Adherence to treatment along with other treatments while the protocol for inhalation timing is followed </h6> <p>The number of returned vials was reported by van der Giessen to give a 97% adherence rate (range 82% to 100%), but no between‐group comparison was reported (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). </p> </section> <section id="CD007923-sec-0120"> <h6 class="title">7. Adverse effects such as bronchospasm, cough and acute decline in pulmonary function</h6> <p>Bedtime inhalation did not adversely impact overnight oximetry (mean (SD) in the morning group was 96.2 (1.4) and in the evening group was 96.1 (1.6), P = 0.78). Bedtime inhalation did not adversely impact cough per hour recordings (mean (SD) in the morning group was 3.7 (8) and in the evening group was 3.3 (5), P = 0.85), but between‐group comparison SDs were not provided (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>) (low‐quality evidence). </p> </section> </section> </section> <section id="CD007923-sec-0121"> <h4 class="title">Assessment of heterogeneity  </h4> <p>Meta‐analysis was possible for several outcomes (FEV<sub>1</sub> in litres and % predicted, FVC in litres and % predicted and FEF<sub>25</sub> in litres and % predicted). For all these meta‐analyses, there was low heterogeneity between trials. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007923-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007923-sec-0122"></div> <section id="CD007923-sec-0123"> <h3 class="title" id="CD007923-sec-0123">Summary of main results</h3> <p>The searches identified 115 trial reports, of which five trials (providing data on 122 participants) met our inclusion criteria. All five trials used a cross‐over design. Intervention periods ranged from two to eight weeks. </p> <p>Four trials examined inhalation of dornase alfa before versus after airway clearance techniques. Despite theoretical arguments that one timing regimen may be better than another, meta‐analysis of all the available data showed that inhalation after instead of before airway clearance did not change FEV<sub>1</sub>, MD ‐0.03 litres (95% CI ‐0.08 to 0.03). Similarly, FVC and quality of life were unaffected. Most of the secondary outcomes were also statistically non‐significant. However, FEF<sub>25</sub> was significantly better with dornase alfa inhalation before airway clearance, based on the pooled data from two small trials (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>; <a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>). This evidence of a benefit in small airway function was reinforced by a similar result in FEF<sub>25-75</sub> (<a href="./references#CD007923-bbs2-0004" title="van derGiessenL . Does the timing of inhaled dornase alfa matter?Journal of Cystic Fibrosis2009;8(Suppl 1):S6-9. van derGiessenLJ , deJongsteJC , GosselinkR , HopWC , TiddensHA . RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology2007;42(7):624-30. van derGiessenLJ , GosselinkR , deJongsteJC , HopWCJ , TiddensHAWM . Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. Journal of Cystic Fibrosis2005;4(Suppl):S97. ">van der Giessen 2007a</a>), although this did not reach statistical significance. However, it is difficult to judge the importance of this finding for several reasons. Unlike the well‐established prognostic value of FEV<sub>1</sub>, we are unaware of evidence for the prognostic value of FEF<sub>25</sub>. Therefore, it is difficult to interpret whether or not the magnitude of the effect on FEF<sub>25</sub> is clinically important, although it did not lead to improvements in symptom scores or quality of life. Furthermore, a decrease in flow at low lung volumes is not necessarily specific for small airway disease and interpretation is hazardous if FEV<sub>1</sub> or FVC are abnormal or have varied, or if their ratio is abnormal (<a href="./references#CD007923-bbs2-0064" title="PellegrinoR , ViegiG , BrusascoV , CrapoRO , BurgosF , CasaburiR , et al. Interpretative strategies for lung function tests. European Respiratory Journal2005;26(5):948-68.">Pellegrino 2005</a>). Also, FEF<sub>25</sub> is a highly variable measure in healthy adults (<a href="./references#CD007923-bbs2-0064" title="PellegrinoR , ViegiG , BrusascoV , CrapoRO , BurgosF , CasaburiR , et al. Interpretative strategies for lung function tests. European Respiratory Journal2005;26(5):948-68.">Pellegrino 2005</a>) and has poor repeatability in children and adolescents with CF (<a href="./references#CD007923-bbs2-0056" title="CooperPJ , RobertsonCF , HudsonIL , PhelanPD . Variability of pulmonary function tests in cystic fibrosis. Pediatric Pulmonology1990;8(1):16-22.">Cooper 1990</a>). This high variability and the lack of significant effects on all other outcomes make it uncertain how relevant the observed benefits in small airway function are to the clinical well being of people with CF, especially into adulthood. </p> <p>In one trial, morning versus evening inhalation had no impact on lung function or symptoms (<a href="./references#CD007923-bbs2-0005" title="van der Giessen L Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 1:S6-9. van derGiessenLJ , GosselinkR , HopW , TiddensH . RhDNase before or after going to sleep in children with cystic fibrosis?Journal of Cystic Fibrosis2007;6(Suppl 1):S68. van derGiessenLJ , GosselinkR , HopWC , TiddensHA . Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?European Respiratory Journal2007;30(4):763-8. [MEDLINE: 96279782]">van der Giessen 2007b</a>). Bedtime inhalation had previously been considered a relative contraindication given the hypothesised risk of a reduced therapeutic effect with the absence of an opportunity to expectorate. Concerns had also been raised concerning side effects of nocturnal cough and impaired sleep quality. Given the potential to improve the time burden and acceptability of therapy with the possibility of evening inhalation, this may have significant implications for patient compliance with therapy. Given that only one trial has examined this comparison further trials would improve the precision of these estimates. </p> </section> <section id="CD007923-sec-0124"> <h3 class="title" id="CD007923-sec-0124">Overall completeness and applicability of evidence</h3> <p>The identified trials were of relatively short duration with a timing intervention ranging from two or three weeks, to a maximum of eight weeks in one trial with very small numbers (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>). In addition, none of the trials reported which timing regimen was chosen by participants after trial completion, which may reflect the relative acceptability of the timing regimens overall. </p> <p>The included trials in this review encompassed a diverse CF patient population in age and disease severity as reflected in FEV<sub>1</sub>, however, only one of the included trials was conducted in adults (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>). </p> <p>Observations about participants with chronic <i>P aeruginosa</i> colonisation on post hoc analysis in the Fitzgerald trial should be interpreted with caution (<a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). </p> <p>Two of the trials included only participants who were naive to dornase alfa (<a href="./references#CD007923-bbs2-0002" title="BishopJR ,  ErskineOJ ,  MiddletonPG . Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy2011;57(4):223-9. MiddletonPG , BishopJ . Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults. Pediatric Pulmonology2001;32(Suppl 22):310. [MEDLINE: 97028227]">Bishop 2011</a>; <a href="./references#CD007923-bbs2-0003" title="FitzgeraldDA , HiltonJ , JepsonB , SmithL . A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics2005;116(4):e549-54. FitzgeraldDA , HiltonJ , SmithL , JepsonB . Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial. Pediatric Pulmonology2001;32(Suppl 22):309-10. [MEDLINE: 95392717]">Fitzgerald 2005</a>). It is well‐recognised that some individuals have a marked response when commencing therapy with dornase alfa while others do not (<a href="./references#CD007923-bbs2-0033" title="RamseyBW , AstleySJ , AitkenML , BurkeW , ColinAA , DorkinHL , et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. American Review of Respiratory Disease1993;148(1):145-51. ">Ramsey 1993</a>). The large response of these participants during the first arm of the trial will increase the variability in both groups. This will reduce the ability of the trial to identify a treatment effect due to the timing of dornase alfa. Furthermore, there are no data to confirm whether participants with a large response to dornase alfa were evenly distributed between the groups in these trials. Therefore, there is the potential for this effect to introduce further bias. </p> <p>One additional cross‐over trial with two‐week intervention periods did not meet the type of intervention specified in our protocol (<a href="./references#CD007923-bbs2-0053" title="WilsonCJ , RobbinsLJ , MurphyJM , ChangAB . Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial. Pediatric Pulmonology2007;42(12):1110-6. [MEDLINE: 96279782]">Wilson 2007</a>). Twenty participants were randomised to morning or evening dornase alfa inhalation to create a lung dwell time of long or short duration, since airway clearance techniques were performed in the morning. The data were analysed to assess the effect of long versus short dwell time. Allowing dornase alfa to dwell in the lungs longer (mean 11 hours) before airway clearance improved FEF<sub>25-75</sub> and quality of life significantly more than a short dwell time (0.2 hours). We believe this differs importantly from trials of pre‐ versus post‐airway clearance techniques, because the long dwell time is more than six hours after the previous session of airway clearance techniques. The dornase alfa would therefore not be influenced by several factors that occur immediately after airway clearance. The first is that the airways ‐ particularly the large central airways ‐ are presumably at their most cleared state. The second is that airway clearance techniques can cause transient bronchoconstriction. Finally, airway clearance techniques can cause a transient increase in mucociliary clearance after the techniques are completed. The combination of these effects may affect the pattern of deposition of the dornase alfa and how quickly it is cleared. It is likely that a long dwell time as used in the Wilson trial has a different mechanism of therapeutic effect than the timing regimen we have examined in the trials comparing inhalation of dornase alfa before versus after airway clearance techniques. In vivo trials demonstrate continued enzymatic activity at six hours, and animal studies at 11 hours (<a href="./references#CD007923-bbs2-0065" title="TGA Approved Product Information. Inhaltion Solution (dornase alfa). eMIMS last amendment 2005.">Roche 2005</a>). A longer dwell time therefore, has the potential to maximise the mucolytic effect. It remains unclear if this is optimal if airway clearance is too distant from drug delivery and the liquefied mucus is not cleared. We plan to include this type of intervention in the next update of this review. </p> </section> <section id="CD007923-sec-0125"> <h3 class="title" id="CD007923-sec-0125">Quality of the evidence</h3> <p>Apart from one trial published only in abstract form (<a href="./references#CD007923-bbs2-0001" title="AndersonP , MortonJ . Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis. Journal of Cystic Fibrosis2009;8(Suppl 2):S74. ">Anderson 2009</a>), in relation to the risk of bias domains, the quality of the included trials was moderate. </p> <p>The quality of the evidence as assessed by GRADE ranged from low to very low. Reasons for downgrading the evidence included risks of bias (due to allocation concealment, blinding and incomplete outcome data) and inapplicability due to the limited age range of participants. </p> </section> <section id="CD007923-sec-0126"> <h3 class="title" id="CD007923-sec-0126">Potential biases in the review process</h3> <p>No potential biases in the review process were identified.</p> </section> <section id="CD007923-sec-0127"> <h3 class="title" id="CD007923-sec-0127">Agreements and disagreements with other studies or reviews</h3> <p>A current Cochrane Review considers the evidence for dornase alfa for people with CF, but timing of inhalation is not considered (<a href="./references#CD007923-bbs2-0068" title="YangC , MontgomeryM . Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews2018, Issue 9. Art. No: CD001127. [DOI: 10.1002/14651858.CD001127.pub4]">Yang 2018</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007923-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/urn:x-wiley:14651858:media:CD007923:CD007923-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 1: FEV1 (L)" data-id="CD007923-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_t/tCD007923-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 1: FEV<sub>1</sub> (L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007923-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/urn:x-wiley:14651858:media:CD007923:CD007923-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 2: FEV1 (% pred)" data-id="CD007923-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_t/tCD007923-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 2: FEV<sub>1</sub> (% pred) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007923-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/urn:x-wiley:14651858:media:CD007923:CD007923-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 3: FVC (L)" data-id="CD007923-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_t/tCD007923-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 3: FVC (L)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007923-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/urn:x-wiley:14651858:media:CD007923:CD007923-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 4: FVC (% pred)" data-id="CD007923-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_t/tCD007923-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 4: FVC (% pred)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007923-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/urn:x-wiley:14651858:media:CD007923:CD007923-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 5: FEF25-75 (% pred)" data-id="CD007923-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_t/tCD007923-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 5: FEF<sub>25-75</sub> (% pred) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007923-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/urn:x-wiley:14651858:media:CD007923:CD007923-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 6: FEF25 (L)" data-id="CD007923-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_t/tCD007923-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 6: FEF<sub>25</sub> (L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007923-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/urn:x-wiley:14651858:media:CD007923:CD007923-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 7: FEF25 (% pred)" data-id="CD007923-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_t/tCD007923-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Pre‐ACT versus Post‐ACT, Outcome 7: FEF<sub>25</sub> (% pred) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007923-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/urn:x-wiley:14651858:media:CD007923:CD007923-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Morning versus Evening, Outcome 1: FEV1 (L)" data-id="CD007923-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_t/tCD007923-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Morning versus Evening, Outcome 1: FEV<sub>1</sub> (L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007923-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/urn:x-wiley:14651858:media:CD007923:CD007923-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Morning versus Evening, Outcome 2: FEV1 (% pred)" data-id="CD007923-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_t/tCD007923-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Morning versus Evening, Outcome 2: FEV<sub>1</sub> (% pred) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007923-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/urn:x-wiley:14651858:media:CD007923:CD007923-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Morning versus Evening, Outcome 3: FVC (L)" data-id="CD007923-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_t/tCD007923-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Morning versus Evening, Outcome 3: FVC (L)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007923-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/urn:x-wiley:14651858:media:CD007923:CD007923-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Morning versus Evening, Outcome 4: FVC (% pred)" data-id="CD007923-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_t/tCD007923-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Morning versus Evening, Outcome 4: FVC (% pred)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007923-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/urn:x-wiley:14651858:media:CD007923:CD007923-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Morning versus Evening, Outcome 5: FEF25 (% pred)" data-id="CD007923-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_t/tCD007923-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Morning versus Evening, Outcome 5: FEF<sub>25</sub> (% pred) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/media/CDSR/CD007923/image_n/nCD007923-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007923-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Inhalation of dornase alfa before versus after airway clearance techniques</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>DNase inhalation before versus after ACTs for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults and children with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: DNase inhalation before ACT </p> <p><b>Comparison</b>: DNase inhalation after ACT </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Inhalation after airway clearance</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Inhalation before airway clearance</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> </p> <p>change from baseline</p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.83% (95% CI ‐2.96% to 1.31%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> <p>(4 cross‐over trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊖⊖⊖</p> <p><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive MD indicates an advantage for DNase inhalation before ACT, but difference is not statistically significant. </p> <p>FEV<sub>1</sub> (L) also showed no significant difference between groups. </p> <p>Participants received both ACTs as cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC (% predicted)</b> </p> <p>change from baseline</p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 1.06% (95% CI ‐1.29% to 3.41%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> <p>(2 cross‐over trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive MD indicates an advantage for DNase inhalation before ACT, but difference is not statistically significant. </p> <p>FVC (L) also showed no significant difference between groups.</p> <p>Participants received both ACTs as cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of QoL and symptom scores</b> </p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> <p>(4 cross‐over trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊖⊖⊖</p> <p><b>very low</b><sup>1,2,3,</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 trials reported a variety of QoL scores (CFQ and QWB) and symptom scores covering well‐being, sputum (volume, viscosity and ease of clearance), and cough (daytime and nighttime). No outcome showed a difference due to timing of DNase inhalation in relation to ACTs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEF<sub>25-75</sub> (% predicted)</b> </p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐6.71% (95% CI ‐14.66% to 1.24%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative MD indicates an advantage for DNase inhalation after ACT, but difference is not statistically significant. </p> <p>Participants received both ACTs as cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (see comment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> <p>(4 cross‐over trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊖⊖⊖</p> <p><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistical comparisons were made. Narrative reports included a single episode of haemoptysis after 2 weeks of DNase inhalation which resolved spontaneously with continued treatment. A further trial reported 34 adverse events (27 of these were for pulmonary exacerbations, 4 for musculoskeletal injuries and 3 gastrointestinal events) in 26 out of 52 participants, but we do not know which treatment group these occurred in. 2 trials monitored nighttime cough frequency but the timing of the interventions had no impact on nocturnal cough. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Relative effect and 95% CI presented is adjusted for the cross‐over design of the trials.<br/><b>ACT</b> : airway clearance technique; <b>CFQ</b> : Cystic Fibrosis Questionnaire, <b>CI</b> : confidence interval; <b>CSS</b> : cough symptom score; <b>DNase</b> : dornase alfa; <b>FEF<sub>25-75</sub> </b> : mid‐forced expiratory volume; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MD</b> : mean difference; <b>NA</b> : not applicable; <b>QoL</b> : quality of life; <b>QWB</b> : quality of well‐being scale; <b>VAS</b>: visual analogue scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded once for high risk of bias due to lack of allocation concealment.</p> <p>2. Downgraded once for high risk of bias due to lack of blinding.</p> <p>3. Downgraded once for high risk of bias due to incomplete outcome data.</p> <p>4. Downgraded once for lack of applicability as trials included only children so results are not applicable to adults. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Inhalation of dornase alfa before versus after airway clearance techniques</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#CD007923-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007923-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Morning versus evening inhalation of dornase alfa</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Morning versus evening inhalation of DNase for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults and children with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: morning DNase inhalation </p> <p><b>Comparison</b>: evening DNase inhalation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Evening inhalation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Morning inhalation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> </p> <p>change from baseline</p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐1.30% (95% CI ‐4.18% to 1.58%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative MD indicates an advantage for evening DNase inhalation, but difference is not statistically significant. </p> <p>FEV<sub>1</sub> (L) also showed no significant difference between groups. </p> <p>Participants received both morning and evening DNase inhalation as cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC (% predicted)</b> </p> <p>change from baseline</p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐0.10% (95% CI ‐5.98% to 5.78%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative MD indicates an advantage for evening DNase inhalation, but difference is not statistically significant </p> <p>FVC (L) also showed no significant difference between groups.</p> <p>Participants received both morning and evening DNase inhalation as cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of QoL and symptom scores</b> </p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A variety of VAS scores reported on cough (day and night), sputum (volume and viscosity), appetite and sleep quality; none of which were significantly different as a result of the time of day the DNase was inhaled. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEF<sub>25-75</sub> (% predicted)</b> </p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p>Follow‐up: up to 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (see comment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(1 cross‐over trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistical comparisons made. Narrative reports indicated that evening DNase inhalation did not adversely impact overnight oximetry or cough per hour recordings (but between‐group comparisons were not provided for this outcome). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Relative effect and 95% CI presented is adjusted for the cross‐over design of the trials.<br/><b>ACT</b> : airway clearance technique; <b>CI</b> : confidence interval; <b>CSS</b> : cough symptom score; <b>DNase</b> : dornase alfa; <b>FEF<sub>25-75</sub> </b> : mid‐forced expiratory volume; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MD</b> : mean difference; <b>NA</b> : not applicable; <b>QoL</b> : quality of life; <b>VAS</b>: visual analogue scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded once for lack of applicability as the trial only included children so results are not applicable to adults. </p> <p>2. Downgraded once due to incomplete outcome data.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Morning versus evening inhalation of dornase alfa</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#CD007923-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007923-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Symptom Scores from van der Giessen 2007a</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>DNase before ACT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>DNase after ACT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value (paired t‐test)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS viscosity*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0.2 to 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0.2 to 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS sputum amount*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7 (0 to 5.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1 (0.1 to 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS daytime cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7 (0 to 5.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9 (1 to 7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS nightime cough*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1 (0 to 3.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2 (0 to 5.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSS daytime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 (0 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6 (0 to 3.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSS nighttime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4 (0 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7 (0 to 2.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Data are mean (or median if asterisked) and range<br/>ACT: airway clearance technique<br/>CSS: cough symptom score<br/>VAS: visual analogue scale </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Symptom Scores from van der Giessen 2007a</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#CD007923-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007923-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Symptom scores from van der Giessen 2007b</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Evening</b> </p> <p><b>Mean (SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morning</b> </p> <p><b>Mean (SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS viscosity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS sputum amount</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9 (1.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS daytime coughing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 (1.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS nighttime coughing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (2.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3 (2.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS sleep quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSS daytime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6 (0.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSS nighttime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 (0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CSS: cough symptom score<br/>SD: standard deviation<br/>VAS: visual analogue scale </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Symptom scores from van der Giessen 2007b</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/full#CD007923-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007923-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pre‐ACT versus Post‐ACT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 FEV<sub>1</sub> (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Over 1 week and up to 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.08, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 FEV<sub>1</sub> (% pred) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Over 1 week and up to 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.83 [‐2.96, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 FVC (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Over 1 week and up to 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.05, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 FVC (% pred) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Over 1 week and up to 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [‐1.29, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 FEF<sub>25-75</sub> (% pred) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Over 1 week and up to 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 FEF<sub>25</sub> (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Over 1 week and up to 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.28, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 FEF<sub>25</sub> (% pred) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Over 1 week and up to 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.44 [‐9.23, ‐1.66]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pre‐ACT versus Post‐ACT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007923-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Morning versus Evening</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 FEV<sub>1</sub> (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Over 1 week and up to 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 FEV<sub>1</sub> (% pred) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Over 1 week and up to 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 FVC (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Over 1 week and up to 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 FVC (% pred) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Over 1 week and up to 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 FEF<sub>25</sub> (% pred) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Over 1 week and up to 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Morning versus Evening</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007923.pub6/references#CD007923-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007923.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007923-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007923-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007923-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007923-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD007923-note-0009">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD007923-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007923-note-0012">Polski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007923\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007923\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007923\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007923\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007923\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007923.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007923.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007923.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007923.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007923.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726674670"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007923.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726674674"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007923.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e996e28739368',t:'MTc0MDcyNjY3NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 